Janssen Biotech has entered into a definitive agreement to acquire a privately-held biopharmaceutical company focused on the red-hot field of cancer immunology.
Financial terms of the deal for BeneVir BioPharm are being kept confidential.
SUBSCRIBE
Biohealth Innovation
Founding Member of
